DK3908582T3 - Faste former, som omfatter (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorbenzonitril og salte deraf, og sammensætninger, som omfatter disse, og fremgangsmåder til anvendelse deraf - Google Patents

Faste former, som omfatter (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorbenzonitril og salte deraf, og sammensætninger, som omfatter disse, og fremgangsmåder til anvendelse deraf

Info

Publication number
DK3908582T3
DK3908582T3 DK20703618.7T DK20703618T DK3908582T3 DK 3908582 T3 DK3908582 T3 DK 3908582T3 DK 20703618 T DK20703618 T DK 20703618T DK 3908582 T3 DK3908582 T3 DK 3908582T3
Authority
DK
Denmark
Prior art keywords
dioxopiperidin
oxoisoindolin
fluorobenzonitrile
piperazin
oxy
Prior art date
Application number
DK20703618.7T
Other languages
English (en)
Inventor
Lianfeng Huang
Udaykumar Jain
Hon-Wah Man
Wenju Wu
Zhiwei Yin
Iii Gerald D Artman
Antonio C Ferretti
Paula A Tavares-Greco
Nancy Nienhua Tsou
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of DK3908582T3 publication Critical patent/DK3908582T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK20703618.7T 2019-01-09 2020-01-08 Faste former, som omfatter (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorbenzonitril og salte deraf, og sammensætninger, som omfatter disse, og fremgangsmåder til anvendelse deraf DK3908582T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962790342P 2019-01-09 2019-01-09
PCT/US2020/012687 WO2020146463A1 (en) 2019-01-09 2020-01-08 Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same

Publications (1)

Publication Number Publication Date
DK3908582T3 true DK3908582T3 (da) 2026-01-19

Family

ID=69467745

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20703618.7T DK3908582T3 (da) 2019-01-09 2020-01-08 Faste former, som omfatter (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorbenzonitril og salte deraf, og sammensætninger, som omfatter disse, og fremgangsmåder til anvendelse deraf

Country Status (23)

Country Link
US (3) US11370777B2 (da)
EP (2) EP3908582B1 (da)
JP (1) JP7483722B2 (da)
KR (1) KR102875111B1 (da)
CN (3) CN113597425A (da)
AU (1) AU2020206694B2 (da)
BR (1) BR112021013435A2 (da)
CA (1) CA3125756A1 (da)
DK (1) DK3908582T3 (da)
EA (1) EA202191620A1 (da)
ES (1) ES3059967T3 (da)
FI (1) FI3908582T3 (da)
HR (1) HRP20260065T1 (da)
IL (1) IL284680B1 (da)
LT (1) LT3908582T (da)
MX (1) MX2021008295A (da)
PL (1) PL3908582T3 (da)
PT (1) PT3908582T (da)
RS (1) RS67646B1 (da)
SG (1) SG11202107439XA (da)
SI (1) SI3908582T1 (da)
SM (1) SMT202600018T1 (da)
WO (1) WO2020146463A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020206692B2 (en) 2019-01-09 2025-03-27 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
EP4095132A1 (en) * 2020-01-20 2022-11-30 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, and pharmaceutical composition and use thereof
CN120004860A (zh) * 2020-07-20 2025-05-16 江苏恒瑞医药股份有限公司 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
KR20240013793A (ko) 2021-05-27 2024-01-30 셀진 코포레이션 조합 요법을 사용하는 다발성 골수종의 치료 방법
TW202606669A (zh) * 2024-05-30 2026-02-16 美商西建公司 Ａｒｎｔ降解化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA3010794A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
IL278854B2 (en) * 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego

Also Published As

Publication number Publication date
IL284680A (en) 2021-08-31
HRP20260065T1 (hr) 2026-02-27
KR20210125491A (ko) 2021-10-18
US11370777B2 (en) 2022-06-28
PT3908582T (pt) 2026-01-28
AU2020206694A1 (en) 2021-07-29
AU2020206694B2 (en) 2025-05-22
CN118324742A (zh) 2024-07-12
SI3908582T1 (sl) 2026-03-31
EP3908582A1 (en) 2021-11-17
SG11202107439XA (en) 2021-08-30
EP4725553A3 (en) 2026-06-10
EP3908582B1 (en) 2025-11-12
PL3908582T3 (pl) 2026-03-30
US12391672B2 (en) 2025-08-19
US20200216418A1 (en) 2020-07-09
IL284680B1 (en) 2026-06-01
SMT202600018T1 (it) 2026-03-09
RS67646B1 (sr) 2026-02-27
EP4725553A2 (en) 2026-04-15
LT3908582T (lt) 2026-02-10
MX2021008295A (es) 2021-10-13
CN114394954B (zh) 2024-04-02
FI3908582T3 (fi) 2026-01-27
US20220289713A1 (en) 2022-09-15
WO2020146463A1 (en) 2020-07-16
CN114394954A (zh) 2022-04-26
US20250340536A1 (en) 2025-11-06
JP7483722B2 (ja) 2024-05-15
CA3125756A1 (en) 2020-07-16
KR102875111B1 (ko) 2025-10-23
CN113597425A (zh) 2021-11-02
EA202191620A1 (ru) 2021-11-01
JP2022518175A (ja) 2022-03-14
ES3059967T3 (en) 2026-03-24
BR112021013435A2 (pt) 2021-10-19

Similar Documents

Publication Publication Date Title
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
IL278854A (en) Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile
IL284680A (en) Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
IL269594A (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
EP3644999A4 (en) COMPOSITIONS AND METHOD OF USING 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDINE-3-YL) -1-OXOISOINDOLINE-5-YL) METHYL) -2,2-DIFLUOACETAMIDE
JOP20190109B1 (ar) أشكال بلورية من مثبط أحادي أسيل جليسرول ليباز (magl)
ECSP15004234A (es) Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que comprenden y métodos para utilizar las mismas
PT3952880T (pt) 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona para utilização no tratamento de linfoma não-hodgkin
NZ610746A (en) Methods of treatment using selective bcl-2 inhibitors
DK2155717T3 (da) 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
IL292258A (en) Pharmaceutical preparations comprising (s)-2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 3, discussion and methods of using them
IL284509A (en) Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide
IL284665B1 (en) Pharmaceutical compounds consisting of (S) –4– (4– (4 – (((2– (2,6–dioxopyridin–3–yl) –1–oxoisinolin–4–yl)oxy) METYL) BENZYL) PIPERAZIN–1– YL) –3–FLUOROBENZONITRILE and methods of use thereof
WO2021080931A8 (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
HK40051930A (en) Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
DK1631291T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes
EP3833659A4 (en) METHOD FOR MAKING (S)-N-(3-((2- ((4-((1-ACETYLPYRROLIDIN-3-YL)(METHYL)AMINO)PHENYL)AMINO)-5-METHOXYRIMIDIN-4-YL)OXY ) PHENYL)ACRYLAMIDE, AND RELATED FORMULATIONS
HK40077320A (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
HK40079627A (en) Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
MX382054B (es) Composición farmacéutica que comprende derivado de quinolina o sal del mismo.
HK40050794A (en) Process for manufacture of (s)-n-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy) phenyl)acrylamide, and formulations thereof
EA201890806A1 (ru) Ингибитор рецептора p2x7
HK40004900A (en) Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate